Johnson & Johnson Oklahoma Opioid Trial Verdict Announced – $572 Million Loss for J&J/Janssen

Johnson & Johnson conducted a misleading marketing campaign for their anti-psychotic drug, Risperdal. Approved by the U.S. Food and Drug Administration (FDA) to treat adults with schizophrenia, Johnson & Johnson marketed the drug for use in children.

Johnson & Johnson Oklahoma Opioid Trial Verdict Announced – $572 Million Loss for J&J/Janssen

By Mark A. York, Mass Tort Nexus Media  (MASS TORT NEXUS MEDIA) The first court verdict to come out of the massive litigation over the opioid crisis has resulted in a verdict against Johnson & Johnson for $572 MILLION at 4:05p.m. today, August 26, 2019 in one of the most important drug related lawsuits in […]